Projects per year
A series of 2-aryl-2-(pyridin-2-yl)acetamides were synthesized and screened for their anticonvulsant activity in animal models of epilepsy. The compounds were broadly active in the 'classical' maximal electroshock seizure (MES) and subcutaneous Metrazol (scMET) tests as well as in the 6 Hz and kindling models of pharmacoresistant seizures. Furthermore, the compounds showed good therapeutic indices between anticonvulsant activity and motor impairment. Structure-activity relationship (SAR) trends clearly showed the highest activity resides in unsubstituted phenyl derivatives or compounds having ortho- and meta- substituents on the phenyl ring. The 2-aryl-2-(pyridin-2-yl)acetamides were derived by redesign of the cardiotoxic sodium channel blocker Disopyramide (DISO). Our results show that the compounds preserve the capability of the parent compound to inhibit voltage gated sodium currents in patch-clamp experiments; however, in contrast to DISO, a representative compound from the series 1 displays high levels of cardiac safety in a panel of in vitro and in vivo experiments.
|Number of pages||14|
|Early online date||5 Mar 2020|
|Publication status||Published - 1 May 2020|
- voltage-gated sodium channel
- sodium channel blocker
- drug discovery
- structure-activity relationships
- anticonvulsant agent
- refractory epilepsy
- drug repositioning
- medicinal chemistry
- cardiac safety
FingerprintDive into the research topics of 'Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide'. Together they form a unique fingerprint.
- 1 Finished
New pathogenic mechanisms in the long QT syndrome: KCNE1 modulation of hERG.
29/03/15 → 28/09/17